Colistin

Summary

Colistin (CHEMBL6067481) is an approved unknown (ATC A07AA10); indicated across 10 conditions including bacterial infectious disease and pneumonia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: A07AA10 (+1 more)
• Indications: 10 conditions
• Clinical trials: 45

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067481
Name	Colistin
Type	Unknown
Max phase	4
ATC	A07AA10, J01XB01

Also known as: Colistin, Colistina, Colistine, Polymyxin e, Sogecoli, colistin, colistine, Polymyxin E1, Polymyxin E, Colistin A, COLISTINE, COLISTIN

Parent form; salt/anhydrous children: CHEMBL6067482

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Receptor tyrosine-protein kinase erbB-2, Tyrosine-protein kinase Fyn, Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Sodium-dependent dopamine transporter, 3’,5’-cyclic-AMP phosphodiesterase 4A, Melanocortin receptor 4, LSD1/CoREST complex, Melanocortin receptor 5, Melanocortin receptor 3.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MC3R	6.78	Ki	168	nM	CHEMBL_ACT_7693340
KDM1A	6.71	Ki	193	nM	CHEMBL_ACT_24984227
MC3R	6.71	IC50	193	nM	CHEMBL_ACT_7693339
MC5R	6.6	Ki	249	nM	CHEMBL_ACT_7693344
MC5R	6.58	IC50	266	nM	CHEMBL_ACT_7693343
KDM1A	6.23	Kd	594	nM	CHEMBL_ACT_22421039
MC4R	6.09	Ki	809	nM	CHEMBL_ACT_7693342
MC4R	6.08	IC50	841	nM	CHEMBL_ACT_7693341
FYN	6.02	IC50	959	nM	CHEMBL_ACT_7693415
EGFR	5.82	IC50	1500	nM	CHEMBL_ACT_7693413
ERBB2	5.65	IC50	2227	nM	CHEMBL_ACT_7693417

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
pneumonia	3	MONDO:0005249	EFO:0003106
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
bronchitis	3	MONDO:0003781	EFO:0009661
cystic fibrosis	3	MONDO:0009061	MONDO:0009061
bacterial infectious disease with sepsis	2	MONDO:0005229	EFO:0003033
neoplasm	2	MONDO:0005070	MONDO:0004992
osteomyelitis	0	MONDO:0005246	EFO:0003102
brain disorder	0	MONDO:0005560	HP:0001298

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 45.

Phase distribution

Phase	Trials
PHASE3	19
PHASE4	13
Not specified	7
PHASE2	3
PHASE2/PHASE3	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05922124	PHASE4	RECRUITING	Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
NCT06570850	PHASE4	RECRUITING	Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection
NCT07004049	PHASE4	RECRUITING	Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT01732250	PHASE4	COMPLETED	Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
NCT01761487	PHASE4	UNKNOWN	SDD for Eradicating CRKP Carriage
NCT02081560	PHASE4	UNKNOWN	Colistin Pharmacokinetics in Continuous Renal Replacement Therapy
NCT02117986	PHASE4	UNKNOWN	Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients
NCT02918409	PHASE4	COMPLETED	IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
NCT04489459	PHASE4	UNKNOWN	Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
NCT04995133	PHASE4	UNKNOWN	Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.
NCT05542446	PHASE4	TERMINATED	Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation
NCT05586815	PHASE4	UNKNOWN	Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
NCT06827756	PHASE4	COMPLETED	Comparative Study of Secondary Prophylaxis for SBP
NCT07089186	PHASE3	RECRUITING	Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
NCT07326540	PHASE3	RECRUITING	Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
NCT00300560	PHASE3	UNKNOWN	Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli
NCT00645723	PHASE3	UNKNOWN	Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
NCT00920270	PHASE3	UNKNOWN	Nebulized Colistin for Hospital-Acquired Pneumonia
NCT01292031	PHASE3	COMPLETED	Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)
NCT01297855	PHASE3	UNKNOWN	Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
NCT01297894	PHASE3	UNKNOWN	Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii
NCT01501968	PHASE3	UNKNOWN	Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity
NCT01577862	PHASE3	COMPLETED	Colistin and Rifampicin for MDR-Acinetobacter
NCT01597973	PHASE3	COMPLETED	Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
NCT01970371	PHASE3	COMPLETED	A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
NCT02619786	PHASE3	UNKNOWN	Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin
NCT02806141	PHASE3	TERMINATED	Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
NCT03341741	PHASE3	COMPLETED	Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients
NCT03622450	PHASE2/PHASE3	COMPLETED	The Effect of Colistin Inhalation on Ventilator Associated Pneumonia
NCT03894046	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
NCT05258851	PHASE3	TERMINATED	Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
NCT05613361	PHASE3	UNKNOWN	The Effect of Curcumin Against Colistin-induced Nephrotoxicity
NCT05689229	PHASE3	COMPLETED	Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial
NCT07524920	PHASE2	NOT_YET_RECRUITING	Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
NCT01035853	PHASE2	COMPLETED	Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
NCT02472600	PHASE2	UNKNOWN	Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
NCT02408185	PHASE1	COMPLETED	Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients
NCT05279586	EARLY_PHASE1	UNKNOWN	Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
NCT06230614	Not specified	RECRUITING	Effect of Diluent Volume on Colistin Inhalation Therapy
NCT06472271	Not specified	RECRUITING	Colistin Dosage Prsonalization Approach

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).